DOCSLIB.ORG

TITLE PAGE SHORT COMMUNICATION Spironolactone

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TITLE PAGE SHORT COMMUNICATION Spironolactone DMD Fast Forward. Published on March 19, 2010 as DOI: 10.1124/dmd.110.032870 DMD FastThis article Forward. has not beenPublished copyedited on and March formatted. 19, The 2010 final version as doi:10.1124/dmd.110.032870 may differ from this version. DMD #32870 TITLE PAGE SHORT COMMUNICATION Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney Downloaded from microsomal aldosterone 18β-glucuronidation: A potential drug interaction. Kathleen M Knights, Kushari Bowalgaha and John O Miners dmd.aspetjournals.org Department of Clinical Pharmacology, Flinders University School of Medicine, Adelaide, Australia at ASPET Journals on September 28, 2021 1 Copyright 2010 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on March 19, 2010 as DOI: 10.1124/dmd.110.032870 This article has not been copyedited and formatted. The final version may differ from this version. DMD #32870 RUNNING TITLE PAGE Running title: Spironolactone and canrenone inhibit aldosterone glucuronidation Corresponding author: Professor Kathleen M Knights, Department of Clinical Pharmacology, Flinders University School of Medicine, Flinders Medical Centre, Bedford Park, SA 5042, Australia Downloaded from Telephone: 61 8 8204 4331 Fax: 61 8 82045114; E-mail: [email protected] dmd.aspetjournals.org Word count: Abstract - 248, Introduction - 382, Results and Discussion - 829 Text pages: 18 at ASPET Journals on September 28, 2021 Number of tables: 1 Number of figures: 2 Number of references: 23 Abbreviations: ALDO, aldosterone; HLM, human liver microsomes; HKCM, human kidney cortical microsomes; Ki, inhibitor constant; 4MU, 4-methylumbelliferone; UGT, UDP-glucuronosyltransferase. 2 DMD Fast Forward. Published on March 19, 2010 as DOI: 10.1124/dmd.110.032870 This article has not been copyedited and formatted. The final version may differ from this version. DMD #32870 ABSTRACT Elevated plasma concentrations of aldosterone (ALDO) are observed in patients treated with spironolactone. Since ALDO is eliminated via UGT2B7-catalyzed 18β- glucuronidation, this study aimed to determine whether spironolactone and its primary metabolites canrenone and canrenoic acid inhibit ALDO 18β-glucuronidation by recombinant UGT2B7 and by human liver- (HLM) and human kidney cortical- (HKCM) microsomes. Initial experiments characterized the effects of all three Downloaded from compounds on 4-methylumbelliferone (4MU) and ALDO glucuronidation by recombinant human UGT2B7. IC50 values for spironolactone and canrenone were in the range 26-50 µM whereas canrenoic acid was a weak inhibitor. Ki values for dmd.aspetjournals.org spironolactone and canrenone inhibition of ALDO 18β-glucuronidation were subsequently determined with HLM, HKCM and UGT2B7 as the enzyme sources. β Spironolactone and canrenone were competitive inhibitors of ALDO 18 - at ASPET Journals on September 28, 2021 glucuronidation by HLM, HKCM and UGT2B7. Mean (±) Ki values for spironolactone were 52±22 µM (HLM) and 34±4 µM (HKCM), and for canrenone 41 ±19 µM (HLM) and 23±2 µM (HKCM). Ki values for spironolactone and canrenone inhibition of ALDO 18β-glucuronidation by recombinant UGT2B7 were 23µM and 11 µM, respectively. ‘Actual’ Ki values for spironolactone and canrenone inhibition of ALDO 18β-glucuronidation, which take into account the role of endogenous microsomal inhibitors, are predicted to be 3-5 µM and 2-4 µM, respectively. The data indicate that the elevated ALDO concentrations observed in patients treated with spironolactone may be due, at least in part, to a pharmacokinetic interaction and spironolactone and canrenone should be considered potential inhibitors of the UGT2B7 mediated metabolic clearance of drugs in both liver and kidney. 3 DMD Fast Forward. Published on March 19, 2010 as DOI: 10.1124/dmd.110.032870 This article has not been copyedited and formatted. The final version may differ from this version. DMD #32870 INTRODUCTION Aldosterone (ALDO) promotes sodium and water retention thereby contributing to the development and maintenance of hypertension. Additionally, ALDO induces left ventricular hypertrophy, augments myocardial, vascular and renal fibrosis, and plays a pivotal role in the progression of congestive heart failure. Recognition of the clinical benefits of aldosterone antagonism in hyperaldosteronism, oedematous states, ascites and heart failure led to the introduction of spironolactone (3-(3-oxo-7α acetylthio- Downloaded from 17β-hydroxy-4-androsten-17α-yl) propionic acid γ-lactone), a mineralocorticoid receptor antagonist, into clinical practice in 1960. Although an effective drug, lack of selectivity manifests as progestogenic and antiandrogenic adverse effects and this led dmd.aspetjournals.org to a decline in use. However, in 1999 the Randomized Aldactone Evaluation Study reported a reduction in mortality of 30% in patients with advanced heart failure treated with low dose spironolactone (Pitt et al., 1999). This led to a resurgence in at ASPET Journals on September 28, 2021 both the use of spironolactone to treat heart failure and the incidence of hyperkalemia, a well documented adverse effect of spironolactone (Juurlink et al., 2004). Since potassium drives ALDO secretion, a predicted pharmacodynamic response to spironolactone is an increase in plasma renin and ALDO concentrations (Garthwaite et al., 2004). ALDO is metabolised in the liver to dihydro and tetrahydro derivatives that are subsequently glucuronidated. In contrast, direct glucuronidation of ALDO by the kidney accounts for ~80% of the formation of ALDO 18β-glucuronide (ALDO 18β- G), which is excreted in urine (Bledsoe et al., 1966). Human kidney cortical (HKCM) and human liver (HLM) microsomal ALDO 18β-G formation is catalyzed primarily by UGT2B7 (Knights et al., 2009), which is expressed in both liver and kidney. In humans spironolactone is metabolised to canrenone (~79%), which exists in 4 DMD Fast Forward. Published on March 19, 2010 as DOI: 10.1124/dmd.110.032870 This article has not been copyedited and formatted. The final version may differ from this version. DMD #32870 equilibrium with its hydrolysis product canrenoic acid (Sadee et al., 1973; Karim 1987). Spironolactone reduces the urinary excretion of ALDO 18β-G in humans when the plasma ALDO concentration is elevated (Vetter et al., 1977), and inhibition of ALDO glucuronidation by spironolactone has been demonstrated in the rat (Tsai et al., 1980). Thus, the question arises whether the elevated plasma ALDO concentration observed with spironolactone treatment (Rossing et al., 2005; Schjoedt et al., 2006) arises solely via a pharmacodynamic mechanism or is due, at least in part, to Downloaded from inhibition of ALDO 18β-glucuronidation. The aim of this study was to determine whether spironolactone, canrenone and canrenoic acid inhibit ALDO 18β-G formation by recombinant UGT2B7, HLM and HKCM. dmd.aspetjournals.org at ASPET Journals on September 28, 2021 5 DMD Fast Forward. Published on March 19, 2010 as DOI: 10.1124/dmd.110.032870 This article has not been copyedited and formatted. The final version may differ from this version. DMD #32870 MATERIALS AND METHODS Materials Alamethicin (from Trichoderma viride), ALDO, canrenoic acid, 4- methylumbelliferone (4-MU), 4-methylumbelliferone-β-D-glucuronide (4-MUG), spironolactone and UDP-glucuronic acid (UDPGA; sodium salt) were purchased from Sigma-Aldrich (Sydney, Australia). Canrenone was purchased from Steraloids Inc (Newport, RI). Solvents and other reagents used were of analytical reagent grade. Downloaded from Methods Enzyme sources dmd.aspetjournals.org HKCM and HLM were prepared from human kidney and liver tissue by differential centrifugation, as described previously (Tsoutsikos et al., 2004; Bowalgaha et al., 2005). The four human livers (H7, H12, H29 and H40) and kidneys (K5, K9, K 10 at ASPET Journals on September 28, 2021 and K11) were obtained from either the human liver ‘bank’ of the Department of Clinical Pharmacology, Flinders Medical Centre or the joint Flinders Medical Centre/Repatriation General Hospital Tissue Bank. HKCM and HLM were activated by pre-incubation with alamethicin, 50 µg/mg microsomal protein (Boase and Miners, 2002). UGT2B7 was stably expressed in a human embryonic kidney cell line (HEK293) according to Stone et al. (2003). Cells expressing UGT2B7 were lysed by sonication. The lysate was centrifuged at 12,000 g for 1 min at 4°C and the supernatant fraction was separated and stored in phosphate buffer (0.1 M, pH 7.4) at – 80°C until use. Expression was demonstrated by immunoblotting with an antibody raised against purified mouse UGT (Uchaipichat et al., 2004) and activity measurement (see Results). Spironolactone, canrenone and canrenoic acid inhibition studies 6 DMD Fast Forward. Published on March 19, 2010 as DOI: 10.1124/dmd.110.032870 This article has not been copyedited and formatted. The final version may differ from this version. DMD #32870 Spironolactone, canrenone and canrenoic acid (10, 100, and 250 μM in phosphate buffer 0.1M, pH 7.4) were screened initially as inhibitors of recombinant UGT2B7 using 4MU and ALDO as the probe substrates. The concentrations of 4MU and ALDO present in incubations were 400 µM and 300 µM respectively, which correspond to the approximate S50/Km values for each compound (Uchaipichat et al., 2004; Knights et al., 2009). Subsequently, Ki values were determined for spironolactone and canrenone inhibition of ALDO 18β-glucuronidation with HLM, Downloaded from HKCM and UGT2B7 as the
Load more

Recommended publications
  • Compositions Comprising Drospirenone Molecularly
    (19) & (11) EP 1 748 756 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/107 (2006.01) 29.04.2009 Bulletin 2009/18 A61K 9/48 (2006.01) A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 9/14 (2006.01) (2006.01) (2006.01) (21) Application number: 05708751.2 A61K 9/70 A61K 31/565 (22) Date of filing: 10.03.2005 (86) International application number: PCT/IB2005/000665 (87) International publication number: WO 2005/087194 (22.09.2005 Gazette 2005/38) (54) COMPOSITIONS COMPRISING DROSPIRENONE MOLECULARLY DISPERSED ZUSAMMENSETZUNGEN AUS DROSPIRENON IN MOLEKULARER DISPERSION DES COMPOSITIONS CONTENANT DROSPIRENONE A DISPERSION MOLECULAIRE (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • FUNKE, Adrian HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR D-14055 Berlin (DE) Designated Extension States: • WAGNER, Torsten AL BA HR MK YU 13127 Berlin (DE) (30) Priority: 10.03.2004 EP 04075713 (74) Representative: Wagner, Kim 10.03.2004 US 551355 P Plougmann & Vingtoft a/s Sundkrogsgade 9 (43) Date of publication of application: P.O. Box 831 07.02.2007 Bulletin 2007/06 2100 Copenhagen Ø (DK) (60) Divisional application: (56) References cited: 08011577.7 / 1 980 242 EP-A- 1 260 225 EP-A- 1 380 301 WO-A-01/52857 WO-A-20/04022065 (73) Proprietor: Bayer Schering Pharma WO-A-20/04041289 US-A- 5 569 652 Aktiengesellschaft US-A- 5 656 622 US-A- 5 789 442 13353 Berlin (DE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • An Unexpected Target for Androgen Deprivation Therapy with Prognosis and Diagnostic Implications
    Author Manuscript Published OnlineFirst on October 11, 2013; DOI: 10.1158/0008-5472.CAN-13-1462 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Androgen glucuronidation: an unexpected target for androgen deprivation therapy with prognosis and diagnostic implications. Laurent Grosse1, Sophie Pâquet1, Patrick Caron1, Ladan Fazli2, Paul S. Rennie2, Alain Bélanger3 and Olivier Barbier1 1Laboratory of Molecular Pharmacology, CHU-Québec Research Centre and Faculty of Pharmacy, Laval University, Québec, Canada 2 Vancouver Prostate Centre at VGH, University of British Columbia, Vancouver, British Columbia, Canada. 3CHU-Québec Research Centre and Faculty of Medicine, Laval University, Québec, Canada Running title: Ablation therapy improves androgen glucuronidation in PCa Keywords: Prostate cancer, androgen ablation therapy, glucuronidation, biomarker, drug target. Financial support: This study was supported by grants from the Canadian Institutes of Health Research (CIHR), the Terry Fox foundation and the Canadian Foundation for Innovation. S. Pâquet is holder of scholarships from CIHR and the Fonds pour la Recherche en Santé du Québec (FRSQ). L. Grosse is supported by a scholarship from the Fonds pour l’Enseignement et la Recherche (FER) from the Faculty of Pharmacy, Laval University (Québec). O. Barbier is holder of salary grants from the CIHR (New Investigator Award #MSH95330) and FRSQ (Junior 2 Scholarship). Address correspondence to: Olivier Barbier, Ph.D. Laboratory of Molecular Pharmacology CHU-Québec Research Centre 2705, boulevard Laurier Québec (QC) G1V 4G2, Canada Phone: 418 654 2296 Fax: 418 654 2769 Email: [email protected] Conflict of interests: Authors have nothing to disclose. Downloaded from cancerres.aacrjournals.org on September 26, 2021.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Downloaded 9/24/2021 7:05:26 PM
    Environmental Science Processes & Impacts PAPER View Article Online View Journal | View Issue Solid-phase extraction as sample preparation of water samples for cell-based and other in vitro Cite this: Environ. Sci.: Processes Impacts,2018,20,493 bioassays† a bc d b Peta A. Neale, Werner Brack, Selim A¨ıt-A¨ıssa, Wibke Busch, ef b d Juliane Hollender, Martin Krauss, Emmanuelle Maillot-Marechal,´ Nicole A. Munz,ef Rita Schlichting,b Tobias Schulze, b Bernadette Voglere and Beate I. Escher *abg In vitro bioassays are increasingly used for water quality monitoring. Surface water samples often need to be enriched to observe an effect and solid-phase extraction (SPE) is commonly applied for this purpose. The applied methods are typically optimised for the recovery of target chemicals and not for effect recovery for bioassays. A review of the few studies that have evaluated SPE recovery for bioassays showed a lack of experimentally determined recoveries. Therefore, we systematically measured effect recovery of a mixture of 579 organic chemicals covering a wide range of physicochemical properties that were spiked into a pristine water sample and extracted using large volume solid-phase extraction (LVSPE). Assays indicative of activation of xenobiotic metabolism, hormone receptor-mediated effects and adaptive stress responses were applied, with non-specificeffects determined through cytotoxicity measurements. Overall, effect recovery was found to be similar to chemical recovery for the majority of bioassays and LVSPE blanks had no effect. Multi-layer SPE exhibited greater recovery of spiked chemicals compared to LVSPE, but the blanks triggered cytotoxicity at high enrichment. Chemical recovery data together with single chemical effect data were used to retrospectively estimate with reverse recovery modelling that there was typically Received 19th November 2017 less than 30% effect loss expected due to reduced SPE recovery in published surface water monitoring Accepted 15th February 2018 studies.
    [Show full text]
  • Conjugated Estrogens Sustained Release Tablets) 0.3 Mg, 0.625 Mg, and 1.25 Mg
    PRODUCT MONOGRAPH PrPREMARIN® (conjugated estrogens sustained release tablets) 0.3 mg, 0.625 mg, and 1.25 mg ESTROGENIC HORMONES ® Wyeth Canada Date of Revision: Pfizer Canada Inc., Licensee December 1, 2014 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Submission Control No: 177429 PREMARIN (conjugated estrogens sustained release tablets) Page 1 of 46 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS ......................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................4 ADVERSE REACTIONS ....................................................................................................14 DRUG INTERACTIONS ....................................................................................................20 DOSAGE AND ADMINISTRATION ................................................................................23 OVERDOSAGE ...................................................................................................................25 ACTION AND CLINICAL PHARMACOLOGY ...............................................................25 STORAGE AND STABILITY ............................................................................................28
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Cyproterone Acetate Or Spironolactone in Lowering Testosterone Concentrations for Transgender Individuals Receiving Oestradiol Therapy
    ID: 19-0272 8 7 L Angus et al. Anti-androgens in 8:7 935–940 transfeminine individuals RESEARCH Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy Lachlan Angus1, Shalem Leemaqz2, Olivia Ooi1, Pauline Cundill3, Nicholas Silberstein3, Peter Locke3, Jeffrey D Zajac1 and Ada S Cheung1 1Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, Australia 2Robinson Research Institute, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia 3Equinox Gender Diverse Clinic, Thorne Harbour Health, Fitzroy, Victoria, Australia Correspondence should be addressed to A S Cheung: [email protected] Abstract Background: Oestradiol with or without an anti-androgen (cyproterone acetate or Key Words spironolactone) is commonly prescribed in transfeminine individuals who have not had f transgender persons orchidectomy; however, there is no evidence to guide optimal treatment choice. f transsexualism Objective: We aimed to compare add-on cyproterone acetate versus spironolactone in f gender identity lowering endogenous testosterone concentrations in transfeminine individuals. f gender dysphoria Design: Retrospective cross-sectional study. f androgens Methods: We analysed 114 transfeminine individuals who had been on oestradiol therapy for >6 months in two gender clinics in Melbourne, Australia. Total testosterone concentrations were compared between three groups; oestradiol alone (n = 21), oestradiol plus cyproterone acetate (n = 21) and oestradiol plus spironolactone (n = 38). Secondary outcomes included serum oestradiol concentration, oestradiol valerate dose, blood pressure, serum potassium, urea and creatinine. Results: Median age was 27.0 years (22.5–45.1) and median duration of hormone therapy was 1.5 years (0.9–2.6), which was not different between groups.
    [Show full text]
  • Determination of Spironolactone and Canrenone in Human Plasma by High-Performance Liquid Chromatography with Mass Spectrometry Detection†
    CROATICA CHEMICA ACTA CCACAA, ISSN 0011-1643, e-ISSN 1334-417X Croat. Chem. Acta 84 (3) (2011) 361–366. CCA-3483 Original Scientific Article Determination of Spironolactone and Canrenone in Human Plasma by High-performance Liquid Chromatography with † Mass Spectrometry Detection Laurian Vlase,a Silvia Imre,b,* Dana Muntean,a Marcela Achim,a and Daniela-Lucia Munteanb aDepartment of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, University of Medicine and Pharmacy “Iuliu Haţieganu”, Victor Babeş street 8, RO-400012, Cluj-Napoca, Romania bDepartment of Drug Analysis, Faculty of Pharmacy, University of Medicine and Pharmacy, Gheorghe Marinescu street 38, RO-540139, Târgu-Mureş, Romania RECEIVED SEPTEMBER 30, 2010; REVISED DECEMBER 21, 2010; ACCEPTED JANUARY 17, 2011 Abstract. A new simple, sensitive and LC-MS/MS method for quantification of spironolactone and its me- tabolite, canrenone, in human plasma is proposed. The analytes were analysed on a C18 column at 48 ºC, by using a mobile phase of 58 % methanol, 42 % 10 mmol dm−3 ammonim acetate in water and a flow rate of 1 mL/min. The detection of both analytes in plasma was performed as follows: ESI+, EIC (m/z 169;187;283;305) from m/z 341, after protein precipitation with methanol. Calibration curves were gener- ated over the ranges 2.77–184.50 ng/mL for spironolactone and 2.69–179.20 ng/mL for canrenone by us- ing a weighted (1/y) linear regression. The absolute values of within- and between-run precision and accu- racy for both analytes ranged between 3.1 and 13.9 %, and the mean recovery was 99.7 %.
    [Show full text]
  • Clinical Efficacy of Potassium Canreonate
    Dąbrowski et al. Trials (2020) 21:397 https://doi.org/10.1186/s13063-020-04277-3 STUDY PROTOCOL Open Access Clinical efficacy of potassium canreonate- canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN- AF trial) Rafał Dąbrowski*, Paweł Syska, Justyna Mączyńska, Michał Farkowski, Stefan Sawicki, Agata Kubaszek-Kornatowska, Piotr Michałek, Ilona Kowalik, Hanna Szwed and Tomasz Hryniewiecki Abstract Background: Atrial fibrillation (AF) is the most frequent cardiac arrhythmia which increases the risk of thromboembolic complications and impairs quality of life. An important part of a therapeutic approach for AF is sinus rhythm restoration. Antiarrhythmic agents used in pharmacological cardioversion have limited efficacy and potential risk of proarrhythmia. Simultaneously, underlying conditions of AF should be treated (e.g. electrolyte imbalance, increased blood pressure, neurohormonal disturbances, atrial volume overload). There is still the need for an effective and safe approach to increase AF cardioversion efficacy. This randomized, double-blind, placebo-controlled, superiority clinical study is performed in patients with AF in order to evaluate the clinical efficacy of intravenous canrenone in sinus rhythm restoration. Methods: Eighty eligible patients with an episode of AF lasting less than 48 h are randomized in a 1:1 ratio to receive canrenone or placebo. Patients randomized to a treatment intervention are receiving canrenone intravenously at a dose of 200 mg within 2–3 min. Subjects assigned to a control group obtain the same volume of 0.9% saline within the same time. The primary endpoint includes return of sinus rhythm documented in the electrocardiogram within 2 h after drug or placebo administration.
    [Show full text]
  • Receptor Af®Nity and Potency of Non-Steroidal Antiandrogens: Translation of Preclinical ®Ndings Into Clinical Activity
    Prostate Cancer and Prostatic Diseases (1998) 1, 307±314 ß 1998 Stockton Press All rights reserved 1365±7852/98 $12.00 http://www.stockton-press.co.uk/pcan Review Receptor af®nity and potency of non-steroidal antiandrogens: translation of preclinical ®ndings into clinical activity GJCM Kolvenbag1, BJA Furr2 & GRP Blackledge3 1Medical Affairs, Zeneca Pharmaceuticals, Wilmington, DE, USA; 2Therapeutic Research Department, and 3Medical Research Department, Zeneca Pharmaceuticals, Alderley Park, Maccles®eld, Cheshire, UK The non-steroidal antiandrogens ¯utamide (Eulexin1), nilutamide (Anandron1) and bicalutamide (Casodex1) are widely used in the treatment of advanced prostate cancer, particularly in combination with castration. The naturally occurring ligand 5a-DHT has higher binding af®nity at the androgen receptor than the non-steroidal antiandrogens. Bicalutamide has an af®nity two to four times higher than 2-hydroxy¯utamide, the active metabolite of ¯utamide, and around two times higher than nilutamide for wild-type rat and human prostate androgen receptors. Animal studies have indicated that bicalutamide also exhi- bits greater potency in reducing seminal vesicle and ventral prostate weights and inhibiting prostate tumour growth than ¯utamide. Although preclinical data can give an indication of the likely clinical activity, clinical studies are required to determine effective, well-tolerated dosing regimens. As components of combined androgen blockade (CAB), controlled studies have shown survival bene®ts of ¯utamide plus a luteinising hormone-releasing hormone analogue (LHRH-A) over LHRH-A alone, and for nilutamide plus orchiectomy over orchiectomy alone. Other studies have failed to show such survival bene®ts, including those comparing ¯utamide plus orchiectomy with orchiectomy alone, and nilutamide plus LHRH-A with LHRH-A alone.
    [Show full text]